ClinicalTrials.gg
TerminatedNCT00848107DISTOL-EXTUpdated Jun 18, 2024Results posted

Open-Label Study of Oral Treprostinil in Digital Ulcers

A Phase 2 interventional study of treprostinil diethanolamine in Systemic Sclerosis, sponsored by United Therapeutics. Terminated at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
The TDE-DU-202 extension study was discontinued after the randomized, placebo-controlled TDE-DU-201 study did not meet its primary efficacy objective.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Enrollment
33rd of 142
115 · median 34
Started
2009
with 4 others
Phase 2
54 of 165
10 open now
Registered
34th of 165
by date

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 33rd largest by enrollment of the 142 interventional ones that give a count, is one of 5 that started in 2009, is one of 54 in phase 2, and was the 34th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects with SSc and digital ulcers.

03

Conditions studied

  • Systemic Sclerosis

Keywords

  • systemic sclerosis
  • scleroderma
  • digital ulcers
  • vasculopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible subjects who completed assessments for the final visit of the previous TDE-DU-201 controlled trial and who signed appropriate were eligible to enroll in this extension study.
  • If a female of , the subject must have agreed to continue practicing an acceptable method of (i.e., surgical sterilization, approved hormonal contraceptives, barrier methods [such as a condom or diaphragm] used with a spermicide, or an intrauterine device).

Exclusion criteria

Exclusion Criteria:

  • Have had any change in clinical status that, in the opinion of the Investigator, would pose a safety risk for participation in this extension study;
  • Have been found to be unable to complete study assessments in the previous controlled trial;
  • Have prematurely discontinued study drug during the previous study due to clinical worsening or treatment related adverse events.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Treprostinil

    Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).

    Drug: treprostinil diethanolamine

Interventions

06

What researchers measure

Primary outcomes

  1. Net Ulcer Burden- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment

    Net ulcer burden at any given assessment was defined as the number of "new" or "active" ulcers at that assessment, plus the number of "indeterminate" ulcers at that assessment that had previously been classified as either "active" or "new" at any earlier assessment during the study. The mean change in net ulcer burden from time of study entry was summarized for each scheduled visit assessment.

    Time frame: Baseline and Months 1, 3, 6, 9, 12, and 18

  2. Total Ulcer Number- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment

    The total ulcer number includes all ulcers designated as "active", "indeterminate", or "new" for a given visit. The mean change in the total number of ulcers present from time of study entry was summarized for each scheduled visit assessment.

    Time frame: Baseline and Months 1, 3, 6, 9, 12, and 18

  3. Formation of New Ulcers

    The number and percentage of subjects who developed new ulcers during the study were summarized.

    Time frame: 18 months (or last study visit)

Secondary outcomes

  1. Patient Function and QOL Measure: Scleroderma Health Assessments Questionnaire (SHAQ)- Mean Change From Study Entry in SHAQ Component Scores at Each Scheduled Assessment

    The SHAQ consists of 20 health assessment questionnaire questions with integer responses of 0 (without any difficulty) to 3 (unable to do), and five scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with values ranging from 0.0 to 15.0 centimeters. The questions are divided into eight component domains: Dressing \& Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each domain score is calculated by summing the domain responses and dividing by the number of questions in that domain. Each VAS domain score is calculated by dividing the value in centimeters by 5. SHAQ component and VAS domain score ranges from 0 (least limitation) to 3 (most limitation). The aggregate SHAQ score is calculated by dividing the sum of all domain scores by 13, with a score ranging from 0 (least limitation) to 3 (most limitation).

    Time frame: Baseline and Months 1, 3, 6, and 12

  2. Patient Function and Quality of Life Measure: Cochin Hand Function Scale (CHFS)-Mean Change From Study Entry in CHFS Score at Each Scheduled Assessment

    The CHFS score is derived from 18 validated questions that assess functional disability and handicap due to hand involvement in rheumatoid arthritis. Each answer is scored on a scale with possible integer responses of 0(without difficulty) to 5 (impossible). The CHFS score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS score values can range from 0 (least limitation) to 90 (most limitation), with improvements in function or reduction of limitation indicated a decreased score value. The mean change from study entry in CHFS scores at each scheduled assessment are summarized.

    Time frame: Baseline and Months 1, 3, 6, and 12

07

Results

Posted Feb 7, 2014
Limitations and caveats
Interpretation of the change in digital ulcer status was limited by the lack of a control group and the discontinuation of the study prior to subjects completing all scheduled visits.

Participant flow

Subjects were recruited to enroll in 26 centers in the US, Canada, and the UK in this open-label trial within 14 days of completion of TDE-DU-201. Subjects who prematurely terminated the previous controlled trial were not eligible. Data from the final study visit of the previous trial served as Baseline data and subject blinding was maintained.

Participant flow — Overall Study
MilestoneOral Treprostinil Diethanolamine
Started115
Completed94
Not completed21
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject8
Withdrew: Adverse event9
Withdrew: Death1
Withdrew: Pregnancy1

Outcome measures

SecondaryPatient Function and QOL Measure: Scleroderma Health Assessments Questionnaire (SHAQ)- Mean Change From Study Entry in SHAQ Component Scores at Each Scheduled Assessment

The SHAQ consists of 20 health assessment questionnaire questions with integer responses of 0 (without any difficulty) to 3 (unable to do), and five scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with values ranging from 0.0 to 15.0 centimeters. The questions are divided into eight component domains: Dressing \& Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each domain score is calculated by summing the domain responses and dividing by the number of questions in that domain. Each VAS domain score is calculated by dividing the value in centimeters by 5. SHAQ component and VAS domain score ranges from 0 (least limitation) to 3 (most limitation). The aggregate SHAQ score is calculated by dividing the sum of all domain scores by 13, with a score ranging from 0 (least limitation) to 3 (most limitation).

Time frame:
Baseline and Months 1, 3, 6, and 12
Reported as:
Mean · units on a scale
Patient Function and QOL Measure: Scleroderma Health Assessments Questionnaire (SHAQ)- Mean Change From Study Entry in SHAQ Component Scores at Each Scheduled Assessment
units on a scaleOral Treprostinil Diethanolamine
Month 1-0.01 ± 0.21
Month 30.02 ± 0.23
Month 60.02 ± 0.28
Month 12-0.04 ± 0.27
PrimaryNet Ulcer Burden- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment

Net ulcer burden at any given assessment was defined as the number of "new" or "active" ulcers at that assessment, plus the number of "indeterminate" ulcers at that assessment that had previously been classified as either "active" or "new" at any earlier assessment during the study. The mean change in net ulcer burden from time of study entry was summarized for each scheduled visit assessment.

Time frame:
Baseline and Months 1, 3, 6, 9, 12, and 18
Reported as:
Mean · ulcers
Net Ulcer Burden- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment
ulcersOral Treprostinil Diethanolamine
Month 1-0.77 ± 1.61
Month 3-0.52 ± 2.02
Month 6-0.32 ± 1.19
Month 9-0.52 ± 1.53
Month 12-0.64 ± 1.20
Month 18-1.67 ± 0.58
SecondaryPatient Function and Quality of Life Measure: Cochin Hand Function Scale (CHFS)-Mean Change From Study Entry in CHFS Score at Each Scheduled Assessment

The CHFS score is derived from 18 validated questions that assess functional disability and handicap due to hand involvement in rheumatoid arthritis. Each answer is scored on a scale with possible integer responses of 0(without difficulty) to 5 (impossible). The CHFS score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS score values can range from 0 (least limitation) to 90 (most limitation), with improvements in function or reduction of limitation indicated a decreased score value. The mean change from study entry in CHFS scores at each scheduled assessment are summarized.

Time frame:
Baseline and Months 1, 3, 6, and 12
Reported as:
Mean · units on a scale
Patient Function and Quality of Life Measure: Cochin Hand Function Scale (CHFS)-Mean Change From Study Entry in CHFS Score at Each Scheduled Assessment
units on a scaleOral Treprostinil Diethanolamine
Month 1-1.1 ± 9.7
Month 3-1.2 ± 8.7
Month 6-1.0 ± 9.3
Month 12-2.8 ± 9.7
PrimaryTotal Ulcer Number- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment

The total ulcer number includes all ulcers designated as "active", "indeterminate", or "new" for a given visit. The mean change in the total number of ulcers present from time of study entry was summarized for each scheduled visit assessment.

Time frame:
Baseline and Months 1, 3, 6, 9, 12, and 18
Reported as:
Mean · number of ulcers
Total Ulcer Number- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment
number of ulcersOral Treprostinil Diethanolamine
Month 1-0.23 ± 1.36
Month 3-0.24 ± 1.99
Month 6-0.21 ± 1.21
Month 9-0.46 ± 1.57
Month 12-0.61 ± 1.20
Month 18-1.67 ± 0.58
PrimaryFormation of New Ulcers

The number and percentage of subjects who developed new ulcers during the study were summarized.

Time frame:
18 months (or last study visit)
Reported as:
Number · participants
Formation of New Ulcers
participantsOral Treprostinil Diethanolamine
No new ulcers48
At least one new ulcer formed63
Indeterminate / missing data4

Adverse events

Collected over 48 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Treprostinil Diethanolamine—17/115 (14.8%)113/115 (98.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventOral Treprostinil Diethanolamine
GastroenteritisInfections and infestations6/115
AnemiaBlood and lymphatic system disorders2/115
Skin ulcerSkin and subcutaneous tissue disorders2/115
Renal failure acuteRenal and urinary disorders2/115
Infected skin ulcerInfections and infestations1/115
InfectionInfections and infestations1/115
OsteomyelitisInfections and infestations1/115
PneumoniaInfections and infestations1/115
Respiratory tract infectionInfections and infestations1/115
PancytopeniaBlood and lymphatic system disorders1/115
Most frequent other events
Showing 10 of 38
Most frequent other events
EventOral Treprostinil Diethanolamine
HeadacheNervous system disorders74/115
DiarrheaGastrointestinal disorders52/115
NauseaGastrointestinal disorders39/115
FatigueGeneral disorders36/115
Pain in extremityMusculoskeletal and connective tissue disorders29/115
Pain in jawMusculoskeletal and connective tissue disorders29/115
FlushingVascular disorders26/115
DizzinessNervous system disorders22/115
Infected skin ulcerInfections and infestations20/115
ArthralgiaMusculoskeletal and connective tissue disorders19/115

Baseline characteristics

Efficacy was assessed using data obtained at each visit, if available, from all subjects enrolled in this study. Assessments performed after discontinuation of study drug were excluded from the summaries. All subjects who had at least one dose of study drug documented were included in the safety analysis population.

Age, Continuous
Age, Continuous(years)Oral Treprostinil Diethanolamine
Mean50 (21 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Oral Treprostinil Diethanolamine
Female88
Male27
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Oral Treprostinil Diethanolamine
Asian4
Caucasian97
African-American13
Native American1
Not provided1
Years since scleroderma diagnosis
Years since scleroderma diagnosis(years)Oral Treprostinil Diethanolamine
Mean10.9 (0 to 35)
Scleroderma Classification
Scleroderma Classification(participants)Oral Treprostinil Diethanolamine
Limited82
Diffuse33
08

Study locations

26 sites
  • University of Alabama - Birmingham - Arthritis Clinical Intervention Program
    Birmingham, Alabama 35294-7201, United States
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • UCLA
    Los Angeles, California 90095-1670, United States
  • Barbara Davis Centre
    Aurora, Colorado 80045, United States
  • University of Connecticut Health Center
    Farmington, Connecticut 06030-1310, United States
  • Georgetown University - Dept. of Medicine/Rheumatology
    Washington, District of Columbia 20007, United States
  • Northwestern University - Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Johns Hopkins University - Division of Rheumatology
    Baltimore, Maryland 21224, United States
  • Boston University School of Medicine
    Boston, Massachusetts 02118-2526, United States
  • University of Michigan - Scleroderma Program
    Ann Arbor, Michigan 48106, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • UMDNJ Clinical Research Center
    New Brunswick, New Jersey 08903, United States
  • North Shore - LIJ Health System
    Lake Success, New York 11042, United States
  • The Hospital for Special Surgery
    New York, New York 10021, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15261, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425-8900, United States
  • University of Texas - Houston
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Virginia Mason Medical
    Seattle, Washington 98101, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • St Joseph's Health Care
    London, Ontario N6A 4V2, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Royal Free Hospital - Center for Rheumatology
    London, NW3 2QG, United Kingdom
  • Salford Royal Hospital
    Manchester, M13 9PT, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 2 years 5 months after primary completion. A results delay was requested in Apr 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2009
First posted
Feb 20, 2009
Start
Sep 2009
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results delay requested
Apr 1, 2013
Results first posted
Feb 7, 2014
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00848107
Responsible party
Sponsor
First posted
Feb 20, 2009
Start date
Sep 2009
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Feb 7, 2014
Last update
Jun 18, 2024

Study contacts

James Seibold, MD
principal investigator · Scleroderma Research Consultants LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion